Bank of Montreal
ZYNE

Bank of Montreal’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Bank of Montreal’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-967
Closed -$3K – 4985
2020
Q2 		$3K Sell
967
-2,798
-74% -$13.2K ﹤0.01% 4502
2020
Q1 		$13K Sell
3,765
-6,146
-62% -$28.5K ﹤0.01% 3407
2019
Q4 		$60K Buy
9,911
+2,703
+38% +$18.5K ﹤0.01% 3762
2019
Q3 		$54K Buy
7,208
+252
+4% +$2.84K ﹤0.01% 3581
2019
Q2 		$94K Buy
+6,956
New +$80.3K ﹤0.01% 3381
2019
Q1 		– Sell
-1,221
Closed -$4K – 4866
2018
Q4 		$4K Buy
1,221
+21
+2% +$115 ﹤0.01% 4194
2018
Q3 		$10K Sell
1,200
-36,300
-97% -$279K ﹤0.01% 3936
2018
Q2 		$365K Buy
+37,500
New +$384K ﹤0.01% 2479
2018
Q1 		– Sell
-1,226
Closed -$15K – 4397
2017
Q4 		$15K Sell
1,226
-41,274
-97% -$473K ﹤0.01% 3677
2017
Q3 		$355K Buy
42,500
+42,316
+22,998% +$447K ﹤0.01% 2423
2017
Q2 		$3K Buy
+184
New +$3.66K ﹤0.01% 3979

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of Montreal's ZYNE Position: Q3 2020 in Review

Bank of Montreal sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2020, closing a stake of 967 shares — an estimated $3K sold.

Bank of Montreal first reported a position in ZYNE in Q2 2017 and held it in 11 quarters. The position peaked at $365K in Q2 2018. 66 funds tracked by Wall St. Rank hold ZYNE as of Q3 2020.

  • Bank of Montreal reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2020 after selling out during the quarter.
  • Bank of Montreal sold 967 Zynerba Pharmaceuticals, Inc shares in Q3 2020, an estimated $3K.
  • Bank of Montreal first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2017 and held it in 11 quarters.
  • Bank of Montreal's Zynerba Pharmaceuticals, Inc position peaked at $365K in Q2 2018.
  • 66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2020.

Based on Bank of Montreal's 13F filing for Q3 2020, filed 12 Nov 2020.